The partners will first develop and validate genotypic diagnostics that provide clinicians with an accurate view of a patient’s risk of disease.
Then, using the molecular profile of their underlying disease mechanisms, they will report back prescribing decisions and drug discovery opportunities to improve patient outcomes.
Last year, PrecisionLife released the results of its long COVID study, revealing that there are genetic risk factors for the disease. The company said this analysis 'opens the door' for new precision diagnostic and therapeutic approaches to treating the condition, which affects over 100 million people globally.
“In Metrodora we have a partner that is focused on the diagnosis and treatment of some of the most challenging and intractable diseases,” said Steve Gardner, CEO of PrecisionLife.
“With our combined disease insights, patient support and clinical expertise, we're building a powerful engine that will transform the rate at which both new diagnostics and effective therapies can be clinically validated and provided to patient communities that are massively underserved – improving health for millions of people.”
According to both companies, the partnership builds on PrecisionLife’s insights into the mechanisms driving over 50 complex diseases and Metrodora’s deep clinical and research expertise.
The collaboration aims to address a broad range of chronic, complex conditions, offering hope to communities of patients who have been underserved until now.
The first products developed will be in long COVID and ME/CFS building on PrecisionLife’s recent studies.
“We’ve gone far too long without providing clinicians and patients with an informative readout of the biological drivers associated with these conditions. Moving with unprecedented speed and scale, we will work to rapidly establish this new class of genotypic diagnostic tools paired with targeted clinical trials at Metrodora,” commented Rohit Gupta, chief scientific officer at Metrodora.
The collaboration will also extend to the identification of drug repurposing candidates associated with disease modifying mechanisms and accelerate the approval of new personalized treatments.
“PrecisionLife's unrivaled understanding of the mechanistic causes of disease enables us to better diagnose individual patients and specify which therapies are most likely to be effective in treating them. Working together we're committed to reimagining treatment for patients with complex neuroimmune axis disorders,” added John Wirthlin, CEO of Metrodora Institute.
